Search results
Results from the WOW.Com Content Network
Reye's syndrome, for example, is a potentially fatal complication of aspirin therapy in children that is very rare in adults. The 2002 Best Pharmaceuticals for Children Act, allowed the FDA to request National Institutes of Health-sponsored testing for pediatric drug testing, although these requests are subject to NIH funding constraints.
The logo of the Drugs for Neglected Diseases initiative (DNDi) The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness (human African trypanosomiasis, HAT), Chagas disease, [1] malaria, filarial ...
The BNF for Children developed from the British National Formulary (BNF), which prior to 2005 had provided information on the treatment of children, with the doses largely determined by calculations based on the body weight of the child. The guidance was provided by pharmacists and doctors whose expertise was in the care of adults.
This is a list of notable medical and scientific journals that publish articles in pharmacology and the pharmaceutical sciences This is a dynamic list and may never be able to satisfy particular standards for completeness.
Pharmaceutical Research is an official journal of the American Association of Pharmaceutical Scientists and covers research spanning the entire spectrum of drug discovery, development, evaluation, and regulatory approval.
AZT trials conducted on HIV-positive African subjects by U.S. physicians and the University of Zimbabwe were performed without proper informed consent. [4] The United States began testing AZT treatments in Africa in 1994, through projects funded by the Centers for Disease Control (CDC), the World Health Organization (WHO) and the National Institutes of Health (NIH).
Joseph Biederman (29 September 1947 – 5 January 2023) was an American academic psychiatrist. He was Chief of the Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD at the Massachusetts General Hospital and a professor of psychiatry at Harvard Medical School.
Phase I: Researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects. Phase II: The study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.